Form 4: Evolent Health Director Acquires Shares

Evolent Health Director Russell Monroe Glass acquired 41,096 shares of Class A Common Stock through a restricted stock unit grant.

Summary

• Russell Monroe Glass, a Director at Evolent Health, Inc., acquired 41,096 shares of Class A Common Stock on June 4, 2026.
• This acquisition was made through restricted stock units granted under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan.
• The securities vest on June 4, 2027, or the date of the Company's 2027 annual meeting, contingent on continued service.
• Following this transaction, Mr. Glass beneficially owns 77,347 shares of Class A Common Stock, with 6,046 shares held indirectly through a trust for the benefit of himself and his spouse.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard director stock grant and acquisition, indicating continued engagement but not necessarily a significant shift in company performance.

Positives

• Director acquisition of shares can signal confidence in the company's future prospects.
• The acquisition of 41,096 shares represents a significant addition to the director's holdings.

Risks

• Vesting of the acquired securities is contingent on the reporting person's continued service, implying a risk of forfeiture if service is terminated before the vesting date.

Future Outlook

The acquired restricted stock units are set to vest on June 4, 2027, or the date of the Company's 2027 annual meeting, subject to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that insider transactions, such as this Form 4 filing by a director, are common in the healthcare technology sector as a means of executive compensation and alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but it does not represent a new capital infusion or change in company strategy.

Next Steps

• Vesting of restricted stock units on June 4, 2027, or the 2027 annual meeting date, contingent on continued service.

Key Dates

Keywords

Evolent Health, EVH, Form 4, Insider Transaction, Director, Restricted Stock Units, Class A Common Stock, Beneficial Ownership